SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is experiencing intense buying pressure and volatility as investors speculate on potential buyout scenarios, upcoming clinical trial milestones, and a squeeze on heavily shorted shares. The community remains highly focused on maintaining long positions, with many users actively encouraging others to ignore pre-market dips and avoid selling into short-seller scare tactics while they await major company catalysts.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is gaining investor attention as it prepares to initiate a pivotal Phase 3 clinical trial for its lead candidate in non-small cell lung cancer, a major catalyst that follows its established Phase 3 success in prostate cancer. The community is actively discussing the stock's significant long-term upside potential, citing the recent hiring of a new Chief Commercial Officer and expectations that the company is a prime candidate for a multi-billion dollar acquisition by major pharmaceutical players.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending as investors react to a significant earnings beat and a massive $1.2 billion backlog, signaling strong demand despite some investor caution regarding forward guidance and margin pressure. The community is actively debating the stock's potential for a short squeeze against concerns over internal accounting risks and class-action legal headwinds.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors react to its recent inclusion in the Russell 3000 index, which has triggered debates over potential institutional buying versus ongoing volatility from heavy short interest. While bulls highlight recent government defense contracts and drone sector momentum as long-term catalysts, community discussion remains polarized by concerns over share dilution and the stock's tendency to face downward pressure after pre-market strength.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is seeing heightened volume and market activity as investors weigh the potential for a strategic buyout or major re-rating driven by its robust pipeline and significant short interest. Community discussions are centered on persistent frustration with current stock performance, speculation about future partnerships, and the critical importance of upcoming clinical data readouts to catalyze a decisive upward trend.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is facing extreme downward pressure amid a barrage of analyst downgrades, analyst price target cuts, and mounting concerns over competition from walled gardens and other ad-tech firms. While some investors argue the company is fundamentally undervalued and a prime turnaround candidate, the community is deeply divided, with many traders expressing frustration over the lack of positive corporate catalysts and aggressive short selling.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is trending as the community closely monitors operational ramp-up progress and potential federal support via the Defense Production Act, while debating the impact of legal disputes with California regulators on the stock's valuation. Investors are actively discussing the company's ability to successfully refinance its debt and achieve targeted production milestones following the start of crude oil sales to Chevron.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is rallying as traders capitalize on the company's emerging solid-state transformer technology, which is being positioned as a key infrastructure play for the booming AI data center market. Community sentiment is currently driven by a mix of heavy short-covering, bullish insider buying, and high expectations for the company to secure major partnerships in the power hardware sector.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors monitor the upcoming closing of its acquisition of TopBuild, with the community actively debating the impact of short interest, recent debt financing success, and the potential for a long-term valuation turnaround. Discussion remains heavily focused on the stock's volatility, dilution concerns, and the conviction among long-term holders that the company's ambitious M&A strategy will unlock significant value as the deal finalizes.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as investors react to a new manufacturing alliance with Toyota and ongoing progress in FAA certification milestones. The community is sharply divided, with bulls pointing to the company's strong cash position and strategic partnerships, while bears continue to highlight concerns over cash burn and potential share dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BLUE ref=$1.18 — NO pstn — but it did give me a vibe of $ORTX Orchard , another commercial gene tx oversold micro biotech, maker of Lebmeldy &amp; Linmeldy, acquired by Kyowa Kirin for $16 cash+$1 CVR on 5 Oct 2023 from $5.00 prior closing.
Biggest diff and 🚩for $BLUE is its trading at + EV with debts and multiple insider sells.
$ORTX was deep neg EV . Was worth buying just for that.

Interestingly, $ORTX was also a rare exception to the rule that reverse split (10-for-1 on 10 Mar 2023) &amp; multiple financings with wrt overhangs (just the latest was 6 March 2023 PIPE $34m @ $0.6 w/ 110% wrt cov) are all bearish. 

In hindsight Mgmt were trying to ensure survival in all scenarios which also helps attract an M&amp;A. Unlike $BLUE (so far).

Side note:  beside ORTX, at least three other recent oversold names were up massive since R/S:
$SGTX Sigilon sold to $LLY Lilly, $HARP Harpoon acquired by $MRK Merck,  $CRIS Curis.

$BLUE   
 
Almost 8 Million cases Globally, that&#39;s a lot of starts my friends  
 
Between 2000 and 2021 total births of babies with sickle cell disease increased globally by 13·7% (95% uncertainty interval 11·1–16·5), to 515 000 (425 000–614 000), primarily due to population growth in the Caribbean and western and central sub-Saharan Africa.  
 
The number of people living with sickle cell disease globally increased from 5·46 million (4·62–6·45) in 2000 to 7·74 million (6·51–9·2) in 2021.

StockTwits Web

Bluebird bio Inc

Frank Mondo

StockTwits for iOS

Curis Inc

Lilly(Eli) & Co

Merck & Co Inc

Orchard Rx Ltd

Harpoon Therapeutics Inc

Sigilon Therapeutics Inc

 ref=$1.18 — NO pstn — but it did give me a vibe of 

 Orchard , another commercial gene tx oversold micro biotech, maker of Lebmeldy & Linmeldy, acquired by Kyowa Kirin for $16 cash+$1 CVR on 5 Oct 2023 from $5.00 prior closing.
Biggest diff and 🚩for 

 is its trading at + EV with debts and multiple insider sells.


 was deep neg EV . Was worth buying just for that.

Interestingly, 

 was also a rare exception to the rule that reverse split (10-for-1 on 10 Mar 2023) & multiple financings with wrt overhangs (just the latest was 6 March 2023 PIPE $34m @ $0.6 w/ 110% wrt cov) are all bearish. 

In hindsight Mgmt were trying to ensure survival in all scenarios which also helps attract an M&A. Unlike 

 (so far).

Side note:  beside ORTX, at least three other recent oversold names were up massive since R/S:


Peter O.

$BLUE BlueBird Bio ref=$1.06 — just following, no pstn — 2Q 10-Q out now:

27 patient starts to date in 2024 (19 ZYNTEGLO, 4 LYFGENIA, 4 SKYSONA)
- Anticipates ~85 patient starts across the portfolio. 
- Q2 net revenue $16.1M
- Anticipates recognizing revenue from first infusion of LYFGENIA in Q3 or Q4
- Cash, equivalents $193M - runway into Q2&#39;25

Debt still a 🚩🚩🚩 for shareholders. Rooting for the company and the patients.

 BlueBird Bio ref=$1.06 — just following, no pstn — 2Q 10-Q out now:

27 patient starts to date in 2024 (19 ZYNTEGLO, 4 LYFGENIA, 4 SKYSONA)
- Anticipates ~85 patient starts across the portfolio. 
- Q2 net revenue $16.1M
- Anticipates recognizing revenue from first infusion of LYFGENIA in Q3 or Q4
- Cash, equivalents $193M - runway into Q2'25

Debt still a 🚩🚩🚩 for shareholders. Rooting for the company and the patients.

$BLUE Bluebird Bio ref=$0.49 — no pstn — big step in the right direction today 👍 Will it be enough for a turnaround a-la $ORTX ? 
Restr + 25% RIF to target break-even in 2H2025

 Bluebird Bio ref=$0.49 — no pstn — big step in the right direction today 👍 Will it be enough for a turnaround a-la 

 ? 
Restr + 25% RIF to target break-even in 2H2025

$BLUE BlueBird time to buy IMO will be when we see execs buying — 🚩 incredible how much they’ve sold much higher and how little skin in the game they have right now for a Co that claims to be turning around with legit business 🚩 as mentioned in the original post 👆🏼, this is one of the key diffs vs ORTX Orchard.
Form 4 list as of today:

 BlueBird time to buy IMO will be when we see execs buying — 🚩 incredible how much they’ve sold much higher and how little skin in the game they have right now for a Co that claims to be turning around with legit business 🚩 as mentioned in the original post 👆🏼, this is one of the key diffs vs ORTX Orchard.
Form 4 list as of today:

$BLUE Bluebird — 🔮 ☝🏽✅🎯 Down 40% on buyout (takeunder!)

Carlyle &amp; SK Capital taking private for $3/share cash (&lt;$30m) + $6.84/share CVR (realized only if product portfolio generates $600M net sales over 12-month period before Dec 2027)

2024-12-12 r/s 1-for-20 float to 9.6M from 192.8M. So at the time of my last posting, split-adj $9.8 -&gt; now $3.00 sale +CVR.

🚩What’s the takeaway here for other GTx / Gene edit co’s of interest? 🧐🤔 $EDIT Editas $DTIL Precision $SGMO Sangamo $MGX Metagenomi etc? 

https://www.businesswire.com/news/home/20250221469479/en/bluebird-bio-Announces-Definitive-Agreement-to-be-Acquired-by-Carlyle-and-SK-Capital

Prior https://stocktwits.com/frontiere/message/586943356

bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by glob

Businesswire

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

BLUE BlueBird time to buy IMO will be when we see execs buying - 🚩 incredible how much they've sold much higher and how little skin in the game they have right now for a Co that claims to be turning around with legit business 🚩 as mentioned in the original post 👆🏼, this is one of the key diffs vs ORTX Orchard.

Stocktwits

Peter O. (@frontiere) | Stocktwits

Sangamo Therapeutics Inc

Editas Medicine Inc

Precision Biosciences Inc

Metagenomi Inc.

 Bluebird — 🔮 ☝🏽✅🎯 Down 40% on buyout (takeunder!)

Carlyle & SK Capital taking private for $3/share cash (<$30m) + $6.84/share CVR (realized only if product portfolio generates $600M net sales over 12-month period before Dec 2027)

2024-12-12 r/s 1-for-20 float to 9.6M from 192.8M. So at the time of my last posting, split-adj $9.8 -> now $3.00 sale +CVR.

🚩What’s the takeaway here for other GTx / Gene edit co’s of interest? 🧐🤔 

@frontiere The answer is when you have crap tech you get peanuts!

 The answer is when you have crap tech you get peanuts!

Mr Rogers

@mike_swiss_r BLUE is not crap tech… stupid comment…

 BLUE is not crap tech… stupid comment…

@frontiere @mike_swiss_r They had loan/funding covenant with Hercules that stated that they needed to come up with an additional $75M in funding by Dec. 10th (if I remember correctly) in order for Hercules to release the next tranch of funding to them. So when they did not receive the PRV (which can be sold for $100M+) they were SOL and skating on thin ice. Trying to launch their SCD product with zero cash. Their competitors got a PRV. So they have big bucks who would love to see them fail so the competition gets the whole pie. They really should have received a PRV also. 
Net/net it doesn&#39;t affect other companies at all except the other guys with the SCD therapy. Many seem to think their therapy is superior, but they got screwed.

 They had loan/funding covenant with Hercules that stated that they needed to come up with an additional $75M in funding by Dec. 10th (if I remember correctly) in order for Hercules to release the next tranch of funding to them. So when they did not receive the PRV (which can be sold for $100M+) they were SOL and skating on thin ice. Trying to launch their SCD product with zero cash. Their competitors got a PRV. So they have big bucks who would love to see them fail so the competition gets the whole pie. They really should have received a PRV also. 
Net/net it doesn't affect other companies at all except the other guys with the SCD therapy. Many seem to think their therapy is superior, but they got screwed.

Chrissie

@Scrood_the_Pooch @mike_swiss_r thanks constructive comment

@frontiere @mike_swiss_r Here in their own words: &quot;Following a comprehensive review of bluebird’s strategic alternatives, including meeting with more than 70 potential investors and partners over a period of five months, and a third and final denial by the Federal Drug Administration of bluebird’s appeal for a priority review voucher, the bluebird Board determined that, absent a significant infusion of capital, bluebird is at risk of defaulting on its loan covenants.&quot;

 Here in their own words: "Following a comprehensive review of bluebird’s strategic alternatives, including meeting with more than 70 potential investors and partners over a period of five months, and a third and final denial by the Federal Drug Administration of bluebird’s appeal for a priority review voucher, the bluebird Board determined that, absent a significant infusion of capital, bluebird is at risk of defaulting on its loan covenants."

@Scrood_the_Pooch @mike_swiss_r to avoid oversimplification…re takeaways for other GTx / Gene edit co’s 🚩:

$PFE Pfizer is ending global dev and comm of Beqvez (fidanacogene elaparvovec), a GTx for hemophilia B, and effectively withdrawing from the gene therapy market…had a US list price of $3.5mn—to “the limited interest patients and their doctors have demonstrated in hemophilia gene therapies,” among other factors. The decision came less than a year after the FDA approved it in April 2024. The company will now focus its hemophilia business on Hympavzi (marstacimab-hncq), a once-weekly tissue factor pathway inhibitor antagonist.
 
PFE no longer has any active GTx progs. In July 2023, it sold a pf of preclin GTx programs &amp; enabling techs to AZN’s Alexion. A year later, it terminated the dev of fordadistrogene movaparvovec for DMD following the failure of Ph3. In Dec 2024, PFE ended an agr w SGMO Sangamo for the joint dev of giroctocogene fitelparvovec for hemophilia A.

Pfizer Inc

 to avoid oversimplification…re takeaways for other GTx / Gene edit co’s 🚩:



 Pfizer is ending global dev and comm of Beqvez (fidanacogene elaparvovec), a GTx for hemophilia B, and effectively withdrawing from the gene therapy market…had a US list price of $3.5mn—to “the limited interest patients and their doctors have demonstrated in hemophilia gene therapies,” among other factors. The decision came less than a year after the FDA approved it in April 2024. The company will now focus its hemophilia business on Hympavzi (marstacimab-hncq), a once-weekly tissue factor pathway inhibitor antagonist.
 
PFE no longer has any active GTx progs. In July 2023, it sold a pf of preclin GTx programs & enabling techs to AZN’s Alexion. A year later, it terminated the dev of fordadistrogene movaparvovec for DMD following the failure of Ph3. In Dec 2024, PFE ended an agr w SGMO Sangamo for the joint dev of giroctocogene fitelparvovec for hemophilia A.

@frontiere And? Just quoting a news item does not take the conversation anywhere! PFE are scrambling, the SGMO Hem A is superior to Roctavian. PFE chose to exit at the 11th hour as they are in a bind over a crap acquisition that will not pay back. SGMO have a different set of issues, the only one front and centre is cash! 
The tech is fine BLUE use a delivery tech that is non-specific, and a drug product that is inferior to a marketed competitor. So unless you have something new to bring conversation ended

 And? Just quoting a news item does not take the conversation anywhere! PFE are scrambling, the SGMO Hem A is superior to Roctavian. PFE chose to exit at the 11th hour as they are in a bind over a crap acquisition that will not pay back. SGMO have a different set of issues, the only one front and centre is cash! 
The tech is fine BLUE use a delivery tech that is non-specific, and a drug product that is inferior to a marketed competitor. So unless you have something new to bring conversation ended